TELA Bio Announces Pricing of $13.0 Million Underwritten Registered Direct Offering of Common Stock and Pre-Funded Warrants
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) priced an underwritten registered direct offering on Nov 13, 2025 comprising 4,189,000 common shares at $1.11 per share and, in lieu of shares, 7,523,000 pre-funded warrants at $1.1099 each (exercise price $0.0001). The gross proceeds are expected to be approximately $13.0 million, before underwriting discounts and offering expenses, assuming no exercise of the pre-funded warrants. The offering is expected to close on or about Nov 17, 2025, subject to customary closing conditions.
Canaccord Genuity is sole bookrunner; the deal was led by Nantahala Capital and EW Healthcare Partners. Proceeds are intended for general corporate purposes, including sales and marketing, R&D, G&A, working capital and capital expenditures. The offering is being made under an SEC-declared Form S-3 shelf registration (File No. 333-275511).
Positive
- Gross proceeds of approximately $13.0 million
- 4,189,000 common shares offered at $1.11 per share
- Deal led by Nantahala Capital and EW Healthcare Partners; Canaccord sole bookrunner
Negative
- Potential issuance of up to 11,712,000 shares if pre-funded warrants are considered (4,189,000 + 7,523,000)
- Pre-funded warrants have a nominal exercise price of $0.0001, creating dilution risk if exercised
- Offering priced at $1.11 per share before fees, which may dilute existing shareholders
News Market Reaction
On the day this news was published, TELA declined 2.63%, reflecting a moderate negative market reaction. Argus tracked a trough of -9.7% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $41M at that time. Trading volume was above average at 1.9x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the pricing of an underwritten registered direct offering of 4,189,000 shares of its common stock at a price of
The offering was led by Nantahala Capital and EW Healthcare Partners.
Canaccord Genuity is acting as the sole bookrunner for the offering.
TELA intends to use the net proceeds from the offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, general and administrative matters, working capital and capital expenditures.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-275511) that was declared effective by the Securities and Exchange Commission (“SEC”) on November 20, 2023. A preliminary prospectus supplement relating to the offering has been filed with the SEC and a final prospectus supplement with the final terms of the offering will be filed with the SEC and will be available for free on the SEC’s website, located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Canaccord Genuity LLC, Attention: Syndication Department, One Post Office Square, Suite 3000, Boston, Massachusetts 02109, or by telephone at (617) 371-3900, or by email at prospectus@cgf.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About TELA Bio, Inc.
TELA Bio, Inc. is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. Such forward-looking statements include, without limitation, statements relating to the completion and use of proceeds of the offering of common stock and pre-funded warrants. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offering, and other risks and uncertainties related to the offering, as well as the risks and uncertainties set forth in the "Risk Factors" section and elsewhere in the prospectus supplement related to the offering filed with the SEC and in our other filings with the SEC and available at www.sec.gov, including in our Annual Report on Form 10-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
What did TELA (NASDAQ: TELA) announce on Nov 13, 2025 regarding financing?
When is the TELA offering expected to close and what conditions apply?
How will TELA use the net proceeds from the Nov 2025 offering?
Who is managing the TELA registered direct offering announced Nov 13, 2025?
What is the dilution impact from TELA's Nov 2025 offering?
Where can investors find the TELA prospectus for the registered direct offering?
